Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Valent

Showing results (151-160 of 662) with videos related to

Pageof 67
Sort By:
The Journal of Allergy and Clinical Immunology. in Practice|August 12, 2018
The Mastocytosis Society Survey on Mast Cell Disorders: Part 2-Patient Clinical Experiences and BeyondNancy Russell, Susan Jennings, Blair Jennings, et al.
The Journal of Allergy and Clinical Immunology|July 14, 2012
Hypoallergenic Der p 1/Der p 2 combination vaccines for immunotherapy of house dust mite allergyKuan-Wei Chen, Katharina Blatt, Wayne R Thomas, et al.
International Journal of Molecular Sciences|June 21, 2019
Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine ApproachesPeter Valent, Cem Akin, Karoline V Gleixner, et al.
Haematologica|December 2, 2016
Is ruxolitinib a potentially useful drug in hematological malignancies with RAS pathway hyperactivation?Klaus Geissler, Eva Jäger, Agnes Barna, et al.
Plos One|November 9, 2013
The transcription factor MAZR preferentially acts as a transcriptional repressor in mast cells and plays a minor role in the regulation of effector functions in response to FcεRI stimulationAnastasia Abramova, Shinya Sakaguchi, Alexandra Schebesta, et al.
Wiener Klinische Wochenschrift|January 21, 2014
Evaluation of treatment responses and colony-forming progenitor cells in 50 patients with aplastic anemia after immunosuppressive therapy or hematopoietic stem cell transplantation: a single-center experienceWolfgang Füreder, Andrea Paulitsch-Buckingham, Werner Rabitsch, et al.
Research and Practice in Thrombosis and Haemostasis|June 17, 2025
Clonal hematopoiesis in patients with cancer and its association with risk of thrombosis and prognosis of diseaseCornelia Englisch, Roland Jäger, Jasmina Gassner, et al.
Wiener Klinische Wochenschrift|September 26, 2015
Probability of remaining in unsustained complete remission after steroid therapy withdrawal in patients with primary warm-antibody reactive autoimmune hemolytic anemiaJohanna Kulpa, Cathrin Skrabs, Ralph Simanek, et al.
International Journal of Molecular Sciences|April 3, 2021
Epigenetic Changes in Neoplastic Mast Cells and Potential Impact in MastocytosisEdyta Reszka, Ewa Jabłońska, Edyta Wieczorek, et al.
American Journal of Blood Research|March 11, 2015
Long-lasting complete response to imatinib in a patient with systemic mastocytosis exhibiting wild type KITPeter Valent, Sabine Cerny-Reiterer, Gregor Hoermann, et al.
Pageof 67

Showing results (151-160 of 662) with videos related to

Sort By:
Pageof 67
The Journal of Allergy and Clinical Immunology. in Practice|August 12, 2018
The Mastocytosis Society Survey on Mast Cell Disorders: Part 2-Patient Clinical Experiences and BeyondNancy Russell, Susan Jennings, Blair Jennings, et al.
The Journal of Allergy and Clinical Immunology|July 14, 2012
Hypoallergenic Der p 1/Der p 2 combination vaccines for immunotherapy of house dust mite allergyKuan-Wei Chen, Katharina Blatt, Wayne R Thomas, et al.
International Journal of Molecular Sciences|June 21, 2019
Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine ApproachesPeter Valent, Cem Akin, Karoline V Gleixner, et al.
Haematologica|December 2, 2016
Is ruxolitinib a potentially useful drug in hematological malignancies with RAS pathway hyperactivation?Klaus Geissler, Eva Jäger, Agnes Barna, et al.
Plos One|November 9, 2013
The transcription factor MAZR preferentially acts as a transcriptional repressor in mast cells and plays a minor role in the regulation of effector functions in response to FcεRI stimulationAnastasia Abramova, Shinya Sakaguchi, Alexandra Schebesta, et al.
Wiener Klinische Wochenschrift|January 21, 2014
Evaluation of treatment responses and colony-forming progenitor cells in 50 patients with aplastic anemia after immunosuppressive therapy or hematopoietic stem cell transplantation: a single-center experienceWolfgang Füreder, Andrea Paulitsch-Buckingham, Werner Rabitsch, et al.
Research and Practice in Thrombosis and Haemostasis|June 17, 2025
Clonal hematopoiesis in patients with cancer and its association with risk of thrombosis and prognosis of diseaseCornelia Englisch, Roland Jäger, Jasmina Gassner, et al.
Wiener Klinische Wochenschrift|September 26, 2015
Probability of remaining in unsustained complete remission after steroid therapy withdrawal in patients with primary warm-antibody reactive autoimmune hemolytic anemiaJohanna Kulpa, Cathrin Skrabs, Ralph Simanek, et al.
International Journal of Molecular Sciences|April 3, 2021
Epigenetic Changes in Neoplastic Mast Cells and Potential Impact in MastocytosisEdyta Reszka, Ewa Jabłońska, Edyta Wieczorek, et al.
American Journal of Blood Research|March 11, 2015
Long-lasting complete response to imatinib in a patient with systemic mastocytosis exhibiting wild type KITPeter Valent, Sabine Cerny-Reiterer, Gregor Hoermann, et al.
Pageof 67